Skip to Main Content

An official website of the United States government

Comparison of the PLCO data with the ovarian cancer screening data in Japan

Principal Investigator
Name
Noriomi Matsumura
Degrees
M.D.
Institution
Kyoto University
Position Title
Associate Professor
Email
About this CDAS Project
Study
PLCO (Learn more about this study)
Project ID
PLCO-56
Initial CDAS Request Approval
Jan 15, 2014
Title
Comparison of the PLCO data with the ovarian cancer screening data in Japan
Summary
We are now planning to generate a new protocol to screen gynecologic cancer, including ovarian, in Japan. We now think that ovarian cancer screening may be effective for type 1 cancer (clear cell, low grade serous, endometrioid and mucinous), not for type 2 high grade serous cancer. In Japan, type 1 cancer is more common than in the Western countries. The PLCO ovarian cancer data will be compared with the data acquired in Japan.
Aims

At present, we want to see the following information.
1) Cancer stage at 0, 1, 2 and 3 years.
We are planning to screen using both ultrasound and CA125. Because the PLCO trial did not use ultrasound at 4-5 years, we want to know the stage distribution if both CA125 and ultrasound are used.
2) Cancer substage.
There is a paper that described that among stage 3 cases, ratio of 3A and 3B was increased by ovarian cancer screening (van Nagel JR, Obstet Gynecol, 2011). Therefore, we want to know if the PLCO study found similar tendency.
3) Ratio of complete surgery.
Recently, the importance of complete surgery has been generally accepted. A Japanese trial found ovarian cancer screening increased the ratio of complete surgery (Kobayashi H, Int J Gynecol Cancer 2008). Therefore, we are interested if the PLCO screening increased the ratio of complete surgery or not.
4) Histological subtype of each tumor

Collaborators

Dr. Masafumi Koshiyama; Kyoto University
Dr. Ikuo Konishi; Kyoto University
Dr. Ryusuke Murakami; Kyoto University